Atrial fibrillation (AF) is the most common type of arrhythmia, characterised by rapid and irregular beating of the atrial chambers of the heart. As a result, the heart can no long pump as much blood around the body, which leads to a wide range of symptoms, disease patterns and co-morbidities.
Featured Learning Zones
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Anticoagulation Therapy for Stroke Prevention
Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.
The causes of arrhythmia are varied and can include diabetes, heart attack or coronary heart disease. They are associated with a large range of conditions and can be classified by their site of origin, mechanism of disturbance, rate of disturbance and electrocardiogram appearance.
Arrhythmias can be acute or chronic and can either be asymptomatic or present with a range of symptoms including dizziness, breathlessness, and palpitations. Asymptomatic arrhythmias can be associated with an increased risk of adverse events such as a higher risk of blood clotting, heart failure, and stroke.
The type and severity of the arrhythmia will determine which treatment is used. In some people no treatment is necessary. For others, treatments can include lifestyle changes, medication (such as antiarrhythmic drugs and anticoagulant therapy), and surgery.
To find out more about cardiac arrhythmia visit our dedicated Learning Zone on anticoagulation for stroke prevention.
Related news and insights
Abbott announced that the FDA has approved the company's next-generation Gallan™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices.
This guideline will be of interest to cardiologists and physicians, dieticians, exercise professionals, general practitioners, health service managers, primary and secondary care nurses, patients, pharmacists, physiotherapists, psychologists, public health staff, specialist nurses, third sector organisations and other healthcare professionals working with patients with cardiac disease.
The scope of this focused update of the 2014 AF Guideline includes revisions to the section on anticoagulation (because of the approval of new medications and thromboembolism protection devices), revisions to the section...